
R version 4.3.1 (2023-06-16) -- "Beagle Scouts"
Copyright (C) 2023 The R Foundation for Statistical Computing
Platform: aarch64-apple-darwin20 (64-bit)

R is free software and comes with ABSOLUTELY NO WARRANTY.
You are welcome to redistribute it under certain conditions.
Type 'license()' or 'licence()' for distribution details.

  Natural language support but running in an English locale

R is a collaborative project with many contributors.
Type 'contributors()' for more information and
'citation()' on how to cite R or R packages in publications.

Type 'demo()' for some demos, 'help()' for on-line help, or
'help.start()' for an HTML browser interface to help.
Type 'q()' to quit R.

> pkgname <- "signifinder"
> source(file.path(R.home("share"), "R", "examples-header.R"))
> options(warn = 1)
> library('signifinder')

> 
> base::assign(".oldSearch", base::search(), pos = 'CheckExEnv')
> base::assign(".old_wd", base::getwd(), pos = 'CheckExEnv')
> cleanEx()
> nameEx("ASCSign")
> ### * ASCSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: ASCSign
> ### Title: Adult Stem Cell Signature
> ### Aliases: ASCSign
> 
> ### ** Examples
> 
> data(ovse)
> ASCSign(dataset = ovse)
ASCSign is using 92% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("CINSign")
> ### * CINSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: CINSign
> ### Title: Chromosomal instability Signature
> ### Aliases: CINSign
> 
> ### ** Examples
> 
> data(ovse)
> CINSign(dataset = ovse, inputType = "rnaseq")
CINSign is using 96% of signature genes
CINSign is using 94% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("CISSign")
> ### * CISSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: CISSign
> ### Title: CIS (carcinoma-in situ) Signature
> ### Aliases: CISSign
> 
> ### ** Examples
> 
> data(ovse)
> CISSign(dataset = ovse)
CISSign is using 28% of up signature genes
Warning in .percentageOfGenesUsed("CISSign", datasetm, sign_up$SYMBOL, "up") :
  CISSignup is computed with less than 30% of its genes
CISSign is using 22% of down signature genes
Warning in .percentageOfGenesUsed("CISSign", datasetm, sign_down$SYMBOL,  :
  CISSigndown is computed with less than 30% of its genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(41): OV_subtype os ... IPSOV_Shen CIS_Robertson
> 
> 
> 
> 
> cleanEx()
> nameEx("DNArepSign")
> ### * DNArepSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: DNArepSign
> ### Title: DNA Repair Signature
> ### Aliases: DNArepSign
> 
> ### ** Examples
> 
> data(ovse)
> DNArepSign(dataset = ovse, inputType = "rnaseq")
DNArepSign is using 87% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("ECMSign")
> ### * ECMSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: ECMSign
> ### Title: Extracellular Matrix Signature
> ### Aliases: ECMSign
> 
> ### ** Examples
> 
> data(ovse)
> ECMSign(dataset = ovse)
ECMSign is using 100% of up signature genes
ECMSign is using 93% of down signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .filterFeatures(expr, method) :
  1 genes with constant expression values throughout the samples.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("EMTSign")
> ### * EMTSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: EMTSign
> ### Title: Epithelial-Mesenchymal Transition Signature
> ### Aliases: EMTSign
> 
> ### ** Examples
> 
> data(ovse)
> EMTSign(dataset = ovse, inputType = "rnaseq")
EMTSignMiow is using 96% of epithelial signature genes
EMTSignMiow is using 91% of mesenchymal signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .filterFeatures(expr, method) :
  1 genes with constant expression values throughout the samples.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("HRDSSign")
> ### * HRDSSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: HRDSSign
> ### Title: Homologous Recombination Deficiency Signature
> ### Aliases: HRDSSign
> 
> ### ** Examples
> 
> data(ovse)
> HRDSSign(dataset = ovse)
HRDSSign is using 89% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("IFNSign")
> ### * IFNSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: IFNSign
> ### Title: IFN-gamma Signature
> ### Aliases: IFNSign
> 
> ### ** Examples
> 
> data(ovse)
> IFNSign(dataset = ovse)
IFNSign is using 100% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("IPRESSign")
> ### * IPRESSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: IPRESSign
> ### Title: IPRES Signature
> ### Aliases: IPRESSign
> 
> ### ** Examples
> 
> data(ovse)
> IPRESSign(dataset = ovse)
IPRESSign is using 100% of signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .filterFeatures(expr, method) :
  92 genes with constant expression values throughout the samples.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
[1] "Normalizing..."
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(41): OV_subtype os ... IPSOV_Shen IPRES_Hugo
> 
> 
> 
> 
> cleanEx()
> nameEx("IPSOVSign")
> ### * IPSOVSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: IPSOVSign
> ### Title: IPSOV Signature
> ### Aliases: IPSOVSign
> 
> ### ** Examples
> 
> data(ovse)
> IPSOVSign(dataset = ovse)
IPSOVSign is using 100% of signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .gsva(expr, mapped.gset.idx.list, method, kcdf, rnaseq, abs.ranking,  :
  Some gene sets have size one. Consider setting 'min.sz > 1'.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("IPSSign")
> ### * IPSSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: IPSSign
> ### Title: ImmunoPhenoScore Signature
> ### Aliases: IPSSign
> 
> ### ** Examples
> 
> data(ovse)
> IPSSign(dataset = ovse)
IPSSign is using 98% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("ISCSign")
> ### * ISCSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: ISCSign
> ### Title: Adult Intestinal Stem Cell Signature
> ### Aliases: ISCSign
> 
> ### ** Examples
> 
> data(ovse)
> ISCSign(dataset = ovse, inputType = "rnaseq")
ISCSign is using 24% of ISCEphB2 signature genes
Warning in .percentageOfGenesUsed("ISCSign", datasetm_n, sign_list$ISCEphB2,  :
  ISCSignISCEphB2 is computed with less than 30% of its genes
ISCSign is using 8% of LateTA signature genes
Warning in .percentageOfGenesUsed("ISCSign", datasetm_n, sign_list$LateTA,  :
  ISCSignLateTA is computed with less than 30% of its genes
ISCSign is using 14% of ISCLgr5 signature genes
Warning in .percentageOfGenesUsed("ISCSign", datasetm_n, sign_list$ISCLgr5,  :
  ISCSignISCLgr5 is computed with less than 30% of its genes
ISCSign is using 42% of Prolif signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(44): OV_subtype os ... ISC_MerlosSuarez_LateTA
  ISC_MerlosSuarez_Prolif
> 
> 
> 
> 
> cleanEx()
> nameEx("PassONSign")
> ### * PassONSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: PassONSign
> ### Title: passON Signature
> ### Aliases: PassONSign
> 
> ### ** Examples
> 
> data(ovse)
> PassONSign(dataset = ovse)
PassONSign is using 100% of signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .filterFeatures(expr, method) :
  1 genes with constant expression values throughout the samples.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
[1] "Normalizing..."
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(41): OV_subtype os ... IPSOV_Shen PassON_Du
> 
> 
> 
> 
> cleanEx()
> nameEx("TLSSign")
> ### * TLSSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: TLSSign
> ### Title: Tertiary Lymphoid Structures (TLS) Signature
> ### Aliases: TLSSign
> 
> ### ** Examples
> 
> data(ovse)
> TLSSign(dataset = ovse)
TLSSign is using 11% of signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, genes, author = author) :
  TLSSign is computed with less than 30% of its genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(41): OV_subtype os ... IPSOV_Shen TLS_Cabrita
> 
> 
> 
> 
> cleanEx()
> nameEx("TinflamSign")
> ### * TinflamSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: TinflamSign
> ### Title: TinflamSign Signature
> ### Aliases: TinflamSign
> 
> ### ** Examples
> 
> data(ovse)
> TinflamSign(dataset = ovse)
TinflamSign is using 100% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("VEGFSign")
> ### * VEGFSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: VEGFSign
> ### Title: VEGF Signature
> ### Aliases: VEGFSign
> 
> ### ** Examples
> 
> data(ovse)
> VEGFSign(dataset = ovse)
VEGFSign is using 100% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("autophagySign")
> ### * autophagySign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: autophagySign
> ### Title: Autophagy Signature
> ### Aliases: autophagySign
> 
> ### ** Examples
> 
> data(ovse)
> autophagySign(dataset = ovse)
autophagySignXu is using 13% of signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, sdata$SYMBOL,  :
  autophagySignXu is computed with less than 30% of its genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(41): OV_subtype os ... IPSOV_Shen Autophagy_Xu
> 
> 
> 
> 
> cleanEx()
> nameEx("availableSignatures")
> ### * availableSignatures
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: availableSignatures
> ### Title: Show Available Signatures
> ### Aliases: availableSignatures
> 
> ### ** Examples
> 
> availableSignatures()
               signature
1               EMT_Miow
2                EMT_Mak
3              EMT_Cheng
4          Pyroptosis_Ye
5        Pyroptosis_Shao
6         Pyroptosis_Lin
7          Pyroptosis_Li
8         Ferroptosis_Ye
9      Ferroptosis_Liang
10       Ferroptosis_Liu
11        Ferroptosis_Li
12 LipidMetabolism_Zheng
13         Hypoxia_Buffa
14       ImmunoScore_Hao
15       ImmunoScore_Roh
16      ConsensusOV_Chen
17       IPS_Charoentong
18    Matrisome_Yuzhalin
19     MitoticIndex_Yang
20      ImmuneCyt_Rooney
21             IFN_Ayers
22  ExpandedImmune_Ayers
23         Tinflam_Ayers
24           TLS_Cabrita
25   StemCellCD49f_Smith
26      Glycolysis_Zhang
27         Glycolysis_Xu
28            CIN_Carter
29    CellCycle_Lundberg
30      CellCycle_Davoli
31          Autophagy_Xu
32       Autophagy_ChenM
33        Autophagy_Wang
34       Autophagy_ChenH
35             ASC_Smith
36      ImmuneCyt_Davoli
37    Chemokines_Messina
38      ISC_MerlosSuarez
39             PassON_Du
40            IPRES_Hugo
41      ECM_Chakravarthy
42         CIS_Robertson
43               HRDS_Lu
44               VEGF_Hu
45           DNArep_Kang
46            IPSOV_Shen
47  GlioCellState_Neftel
                                                                                                                                                      scoreLabel
1                                                                                                                      EMT_Miow_Epithelial, EMT_Miow_Mesenchymal
2                                                                                                                                                        EMT_Mak
3                                                                                                                                                      EMT_Cheng
4                                                                                                                                                  Pyroptosis_Ye
5                                                                                                                                                Pyroptosis_Shao
6                                                                                                                                                 Pyroptosis_Lin
7                                                                                                                                                  Pyroptosis_Li
8                                                                                                                                                 Ferroptosis_Ye
9                                                                                                                                              Ferroptosis_Liang
10                                                                                                                                               Ferroptosis_Liu
11                                                                                                                                                Ferroptosis_Li
12                                                                                                                                         LipidMetabolism_Zheng
13                                                                                                                                                 Hypoxia_Buffa
14                                                                                                                                               ImmunoScore_Hao
15                                                                                                                                               ImmunoScore_Roh
16                                                                        ConsensusOV_Chen_IMR, ConsensusOV_Chen_DIF, ConsensusOV_Chen_PRO, ConsensusOV_Chen_MES
17                                                              IPS_Charoentong, IPS_Charoentong_MHC, IPS_Charoentong_CP, IPS_Charoentong_EC, IPS_Charoentong_SC
18                                                                                                                                            Matrisome_Yuzhalin
19                                                                                                                                             MitoticIndex_Yang
20                                                                                                                                              ImmuneCyt_Rooney
21                                                                                                                                                     IFN_Ayers
22                                                                                                                                          ExpandedImmune_Ayers
23                                                                                                                                                 Tinflam_Ayers
24                                                                                                                                                   TLS_Cabrita
25                                                                                                                                           StemCellCD49f_Smith
26                                                                                                                                              Glycolysis_Zhang
27                                                                                                                                                 Glycolysis_Xu
28                                                                                                                                  CIN_Carter_25, CIN_Carter_70
29                                                                                                                                            CellCycle_Lundberg
30                                                                                                                                              CellCycle_Davoli
31                                                                                                                                                  Autophagy_Xu
32                                                                                                                       Autophagy_ChenM_OS, Autophagy_ChenM_DFS
33                                                                                                                                                Autophagy_Wang
34                                                                                                                                               Autophagy_ChenH
35                                                                                                                                                     ASC_Smith
36                                                                                                                                              ImmuneCyt_Davoli
37                                                                                                                                            Chemokines_Messina
38                                                         ISC_MerlosSuarez_ISCEphB2, ISC_MerlosSuarez_LateTA, ISC_MerlosSuarez_ISCLgr5, ISC_MerlosSuarez_Prolif
39                                                                                                                                                     PassON_Du
40                                                                                                                                                    IPRES_Hugo
41                                                                                                                    ECM_Chakravarthy_up, ECM_Chakravarthy_down
42                                                                                                                                                 CIS_Robertson
43                                                                                                                                                       HRDS_Lu
44                                                                                                                                                       VEGF_Hu
45                                                                                                                                                   DNArep_Kang
46                                                                                                                                                    IPSOV_Shen
47 GlioCellState_Neftel_MES1, GlioCellState_Neftel_MES2, GlioCellState_Neftel_AC, GlioCellState_Neftel_OPC, GlioCellState_Neftel_NPC1, GlioCellState_Neftel_NPC2
          functionName                        topic
1              EMTSign    epithelial to mesenchymal
2              EMTSign    epithelial to mesenchymal
3              EMTSign    epithelial to mesenchymal
4       pyroptosisSign                   pyroptosis
5       pyroptosisSign                   pyroptosis
6       pyroptosisSign                   pyroptosis
7       pyroptosisSign                   pyroptosis
8      ferroptosisSign                  ferroptosis
9      ferroptosisSign                  ferroptosis
10     ferroptosisSign                  ferroptosis
11     ferroptosisSign                  ferroptosis
12 lipidMetabolismSign                   metabolism
13         hypoxiaSign                      hypoxia
14     immunoScoreSign                immune system
15     immunoScoreSign                immune system
16     consensusOVSign             ovarian subtypes
17             IPSSign                immune system
18       matrisomeSign         extracellular matrix
19    mitoticIndexSign                   cell cycle
20       immuneCytSign                immune system
21             IFNSign                immune system
22  expandedImmuneSign                immune system
23         TinflamSign                immune system
24             TLSSign                immune system
25   stemCellCD49fSign                    stem cell
26      glycolysisSign                   metabolism
27      glycolysisSign                   metabolism
28             CINSign      chromosomal instability
29       cellCycleSign                   cell cycle
30       cellCycleSign                   cell cycle
31       autophagySign                    autophagy
32       autophagySign                    autophagy
33       autophagySign                    autophagy
34       autophagySign                    autophagy
35             ASCSign                    stem cell
36       immuneCytSign                immune system
37       chemokineSign                immune system
38             ISCSign                    stem cell
39          PassONSign                immune system
40           IPRESSign                immune system
41             ECMSign         extracellular matrix
42             CISSign            carcinoma lesions
43            HRDSSign      chromosomal instability
44            VEGFSign                 angiogenesis
45          DNArepSign      chromosomal instability
46           IPSOVSign                immune system
47   glioCellStateSign glioblastoma cellular states
                                                                                                tumor
1                                                                                      ovarian cancer
2                                                                                          pan-cancer
3                                                                                       breast cancer
4                                                                                      ovarian cancer
5                                                                                      gastric cancer
6                                                                                 lung adenocarcinoma
7                                                                             glioblastoma multiforme
8                                                                                      ovarian cancer
9                                                                            hepatocellular carcinoma
10                                                                                    prostate cancer
11                                                                       oral squamous cell carcinoma
12                                                                          epithelial ovarian cancer
13                                                                                         pan-cancer
14                                                                          epithelial ovarian cancer
15                                                                                         pan-cancer
16                                                                high-grade serous ovarian carcinoma
17                                                                                         pan-cancer
18 ovarian cystadenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, lung adenocarcinoma
19                                                                                         pan-cancer
20                                                                                         pan-cancer
21                                                                                         pan-cancer
22                                                                                         pan-cancer
23                                                                                         pan-cancer
24                                                                                           melanoma
25                                                                                    prostate cancer
26                                                                                lung adenocarcinoma
27                                                                               renal cell carcinoma
28                                                                                         pan-cancer
29                                                                                         pan-cancer
30                                                                                         pan-cancer
31                                                                                             glioma
32                                                                    clear cell renal cell carcinoma
33                                                                                       glioblastoma
34                                                                                    cervical cancer
35                                                                                         pan-cancer
36                                                                                         pan-cancer
37                                                                                         pan-cancer
38                                                                                  colorectal cancer
39                                                                                metastatic melanoma
40                                                                                metastatic melanoma
41                                                                                         pan-cancer
42                                                                                     bladder cancer
43                                                                      ovarian cancer, breast cancer
44                                                                                         pan-cancer
45                                                                  serous ovarian cystadenocarcinoma
46                                                                                     ovarian cancer
47                                                                                       glioblastoma
                        tissue  cellType      requiredInput
1                        ovary      bulk microarray, rnaseq
2                   pan-tissue      bulk microarray, rnaseq
3                       breast      bulk microarray, rnaseq
4                        ovary      bulk             rnaseq
5                      stomach      bulk microarray, rnaseq
6                         lung      bulk             rnaseq
7                        brain      bulk             rnaseq
8                        ovary      bulk microarray, rnaseq
9                        liver      bulk             rnaseq
10                    prostate      bulk microarray, rnaseq
11                 oral cavity      bulk             rnaseq
12                       ovary      bulk             rnaseq
13                  pan-tissue      bulk microarray, rnaseq
14                       ovary      bulk microarray, rnaseq
15                  pan-tissue      bulk             rnaseq
16                       ovary      bulk microarray, rnaseq
17                  pan-tissue      bulk             rnaseq
18 ovary, lung, stomach, colon      bulk microarray, rnaseq
19                  pan-tissue      bulk             rnaseq
20                  pan-tissue      bulk microarray, rnaseq
21                  pan-tissue      bulk             rnaseq
22                  pan-tissue      bulk             rnaseq
23                  pan-tissue      bulk             rnaseq
24                        skin      bulk microarray, rnaseq
25                    prostate      bulk             rnaseq
26                        lung      bulk             rnaseq
27                      kidney      bulk             rnaseq
28                  pan-tissue      bulk microarray, rnaseq
29                  pan-tissue      bulk microarray, rnaseq
30                  pan-tissue      bulk microarray, rnaseq
31                       brain      bulk             rnaseq
32                      kidney      bulk             rnaseq
33                       brain      bulk             rnaseq
34                      cervix      bulk microarray, rnaseq
35                  pan-tissue      bulk microarray, rnaseq
36                  pan-tissue      bulk microarray, rnaseq
37                  pan-tissue      bulk microarray, rnaseq
38                       colon      bulk microarray, rnaseq
39                        skin      bulk             rnaseq
40                        skin      bulk             rnaseq
41                  pan-tissue      bulk             rnaseq
42                     bladder      bulk             rnaseq
43               ovary, breast      bulk microarray, rnaseq
44                  pan-tissue      bulk microarray, rnaseq
45                       ovary      bulk microarray, rnaseq
46                       ovary      bulk microarray, rnaseq
47                       brain malignant                 sc
                      transformationStep        author
1                  normArray, normCounts          Miow
2                  normArray, normCounts           Mak
3          normArray, log2(normCounts+1)         Cheng
4                                   FPKM            Ye
5                        normArray, FPKM          Shao
6                                    TPM           Lin
7                             normCounts            Li
8                        normArray, FPKM            Ye
9                             normCounts         Liang
10                       normArray, FPKM           Liu
11                            normCounts            Li
12                            normCounts         Zheng
13         normArray, log2(normCounts+1)         Buffa
14            normArray, log2(FPKM+0.01)           Hao
15                    log2(normCounts+1)           Roh
16                 normArray, normCounts          Chen
17                           log2(TPM+1)   Charoentong
18                 normArray, normCounts      Yuzhalin
19                            normCounts          Yang
20                   normArray, TPM+0.01        Rooney
21                   log10(normCounts+1)         Ayers
22                   log10(normCounts+1)         Ayers
23                   log10(normCounts+1)         Ayers
24         normArray, log2(normCounts+1)       Cabrita
25                    log2(normCounts+1)         Smith
26                    log2(normCounts+1)         Zhang
27                    log2(normCounts+1)            Xu
28         normArray, log2(normCounts+1)        Carter
29         normArray, log2(normCounts+1)      Lundberg
30                 normArray, normCounts        Davoli
31                            normCounts            Xu
32                                  FPKM         ChenM
33                            normCounts          Wang
34                 normArray, normCounts         ChenH
35 log2(normArray+1), log2(normCounts+1)         Smith
36                 normArray, normCounts        Davoli
37         normArray, log2(normCounts+1)       Messina
38         normArray, log2(normCounts+1) Merlos-Suarez
39                                   TPM            Du
40                             log2(CPM)          Hugo
41                            normCounts  Chakravarthy
42                            normCounts     Robertson
43                 normArray, normCounts            Lu
44 log2(normArray+1), log2(normCounts+1)            Hu
45          normArray, log2(normCount+1)          Kang
46          normArray, log2(normCount+1)          Shen
47                        log2(TPM/10+1)        Neftel
                                                                      reference
1                                                Miow Q. et al. Oncogene (2015)
2                                          Mak M. et al. Clin Cancer Res (2016)
3                                      Cheng Q. et al. Breast Cancer Res (2014)
4                                        Ye Y. et al. Cell Death Discov. (2021)
5                                  Shao W. et al. Front. Cell Dev. Biol. (2021)
6                                       Lin W. et al. Cell Death Discov. (2021)
7                                           Li X.Y. et al. Front. Oncol. (2021)
8                                       Ye Y. et al. Front. Mol. Biosci. (2021)
9                                       Liang J.Y. et al. Int J Biol Sci (2020)
10                                            Liu H. et al. Front. Oncol (2021)
11                                               Li H. et al. BMC Cancer (2021)
12                                     Zheng M. et al. Int. J. Mol. Sci. (2020)
13                                         Buffa F.M. et al. Br J Cancer (2010)
14                                         Hao D. et al. Clin Cancer Res (2018)
15                                          Roh W. et al. Sci Transl Med (2017)
16                                      Chen G.M. et al. Clin Cancer Res (2018)
17                                       Charoentong P. et al. Cell Rep. (2017)
18                                        Yuzhalin A. et al. Br J Cancer (2018)
19                                            Yang Z. et al. Genome Biol (2016)
20                                               Rooney M.S. et al. Cell (2015)
21                                        Ayers M. et al. J Clin Invest. (2017)
22                                        Ayers M. et al. J Clin Invest. (2017)
23                                        Ayers M. et al. J Clin Invest. (2017)
24                                              Cabrita R. et al. Nature (2020)
25                                                Smith B.A. et al. PNAS (2015)
26                                          Zhang L. et al. J Transl Med (2019)
27                                               Xu F. et al. BMC Cancer (2020)
28                                          Carter S.L. et al. Nat Genet (2006)
29 Lundberg A. et al. Clin Cancer Res (2017) Lundberg A. et al. Oncogene (2020)
30                                              Davoli T. et al. Science (2017)
31                                             Xu Y. et al. Front. Oncol (2020)
32                                           Chen M. et al. Front. Oncol (2020)
33                                      Wang Z. et al. Aging (Albany NY) (2019)
34                                          Chen H. et al. J Ovarian Res (2020)
35                                           Smith B.A. et al. Cell Rep. (2018)
36                                              Davoli T. et al. Science (2017)
37                                           Messina J.L. et al. Sci Rep (2012)
38                                       Merlos-Su√°rez A. Cell Stem Cell (2011)
39                                               Du K. et al. Nat Commun (2021)
40                                                   Hugo W. et al. Cell (2016)
41                                     Chakravarthy A. et al. Nat Commun (2018)
42                                            Robertson A.G. et al. Cell (2017)
43                                                Lu J. et al. J Mol Med (2014)
44                                                  Hu Z. et al. BMC Med (2009)
45                                                   Kang J. et al. JNCI (2012)
46                                                Shen S. et al. EBiomed (2019)
47                                                 Neftel C. et al. Cell (2019)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                description
1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Double score obtained with ssGSEA to establish the epithelial- and the mesenchymal-like status in ovarian cancer patients.
2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Score of the level of epithelial or mesenchymal status in cancer. Positive score is correlated with mesenchymal while negative score with epithelial.
3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Score associates with risk of late recurrence in breast cancer patients. Higher score associates with late recurrencies and bad prognosis.
4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Score is based on risk coefficients and expression data of selected pyroptosis genes selected for their association with survival in ovarian cancer patients. Higher the score higher the risk.
5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Score is based on risk coefficients and expression data of selected pyroptosis genes. It predicts the prognosis and overall survival time: lower PS-score greater inflammatory cell infiltration and better response of immunotherapy .
6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          A pyroptosis-related prognostic gene signature for lung adenocarcinoma patients. Score is based on risk coefficients and expression data of selected pyroptosis genes. Patients with high-risk scores have a worse overall survival probability than those with low-risk scores.
7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  A pyroptosis-related prognostic gene signature for glioblastoma patients. Score is based on risk coefficients and expression data of selected pyroptosis genes. Higher the score worst the prognosis and overall survival and higher immune infiltrates.
8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 A ferroptosis-related prognostic gene signature for ovarian cancers. High scores mean high-risk, poor overall survival and low immune cells infiltration.
9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          A ferroptosis-related prognostic gene signature for hepatocellular carcinoma. High scores mean high-risk, poor overall survival.
10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 A ferroptosis-related prognostic gene signature for hepatocellular carcinoma. High scores mean high-risk, poor recurrence free survival and a better putative response to immunotherapy.
11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                A ferroptosis-related prognostic gene signature for oral squamous cell carcinoma. Patients in high-risk group had a significantly worse overall survival.
12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             A prognostic signature based on lipid metabolism for ovarian cancer patients. Higher the scores higher the risk and poorer the overall survival of patients.
13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         A highly prognostic signature. The score increasement reflects hypoxia activity.
14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            An immune related signature to investigate the in situ immune activity in ovarian cancer and the response to chemotherapy. High immune score displayed overall high expression of favorable prognostic genes.
15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The score is based on expression of genes involved in cytolytic markers, HLA molecules , IFN-Œ≥ pathway genes, chemokines, and adhesion molecules. It is used to investigate immune activation in tumor microenvironment, higher the score higher the immune system activation on relation to tumor rejection.
16                                                                                                                                                                                                                                                                                                                                                                                                                                                           It implements a consensus classifier of the four major subtype classifiers for high-grade serous ovarian cancer as described by Helland et al. (PLoS One, 2011), Bentink et al. (PLoS One, 2012), Verhaak et al. (J Clin Invest, 2013), and Konecny et al. (J Natl Cancer Inst, 2014), thereby providing reliable stratification of patients with high-grade serous ovarian tumors of clearly defined subtype.
17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Five immune related scores are returned: the overall immune score (IPS), the EC score for effector cells (activated CD8+/CD4+ T cells), the SC score for immuno suppressive cells, the MHC score for antigen processing molecules, the CP score for co-inhibitory and co-stimulatory molecules.
18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               A prognostic score based on proteins of the extracellular matrix in different cancer types. Higher scores are associated with poor prognoses and reduced overall survival.
19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The mitotic-index is constructed from genes that have been highly validated as being cell proliferation markers. The score reflects the fraction of dividing cells in a sample and can be used as a predictors of normal/cancer status.
20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         The score is a quantitative measure of immune cytolytic activity based on transcript levels of two key cytolytic effectors, granzyme A and perforin. High scores are associated with counter-regulatory immune responses and improved prognosis.
21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           IFN-Œ≥ Score based on genes related to IFN-Œ≥ predicts clinical response to PD-1 checkpoint blockade. Higher scores are found in responders.  Signature derives from patients undergoing treatment with Pembrolizumab in clinical trials using multiple distinct tumor types. The score is higher in responders.
22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              The score predict clinical response to PD-1 checkpoint blockade based on genes associated with cytolytic activity, pro-inflammatory cytokines/chemokines, T cell markers, NK cell activity, antigen presentation and T cell checkpoints. The score is higher in responders.
23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The score is derived by the expression of T cell‚Äìinflamed representing genes and it predicts the response to Pembrolizumab across multiple solid tumors. A T cell‚Äìinflamed phenotype is necessary for the clinical activity of PD-1‚Äì/PD-L1‚Äìdirected monoclonal antibodies. The score is higher in responders.
24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       TLS consists of B-cells and CD8+T cells. It correlates with a better prognosis. It predict clinical outcomes in cohorts of patients treated with immune checkpoint blockade (ICB).
25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             The score is specific for human prostate basal cells (CD49f Hi) that is differentially enriched in various phenotypes of late-stage metastatic prostate cancer. The score is associated with aggressive and metastatic prostate cancer, higher the score more CD49f HI cells and more aggressive phenotypes.
26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Score is based on risk coefficients and expression data of glycolysis-related genes selected for their association with survival in LUAD patients. Higher the score higher the risk and metastasis formation., low overall survival.
27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Score is based on risk coefficients and expression data of glycolysis-related genes selected for their association with survival in RCC patients. It returns a prognostic risk-score for tumor progression, prognosis. Higher the score worst the prognosis.
28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   The score characterizes aneuploidy in tumor samples based on coordinated aberrations in expression of genes localized to each chromosomal region. Higher the score higher the total level of chromosomal aberration. Net overexpression of this signature was predictive of poor clinical outcome in six cancer types.
29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              It is a representative of general cell-cycle activity and could be applied to any tissue sample. Higher scores represent a worse prognosis.
30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Cell cycle signature score represents the expression of a set of genes considered molecular markers of proliferation. Higher the score higher the proliferation. \nHigh level is associated with high level of SCNA (somatic copy number alterations).
31                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Score is based on autophagy-related genes selected for their association with survival in glioma patients. Higher the score higher the risk, worst the prognosis.
32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           The signature generates two scores based on autophagy-related genes that returns a prognostic risk-scores for clear cell renal cell carcinoma samples: OS - the score predicting the overall survival based on 11 genes, and DFS the score predicting the disease-free survival based on 5 genes. Higher the score, higher the risk, lower the OS/DF survival.
33                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Score is based on autophagy-related genes selected for their association with survival in glioblastoma patients. Higher the score higher the risk, worst the prognosis.
34                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Score is based on autophagy-related genes selected for their association with survival in cervical cancer patients. Higher the score higher the risk, worst the prognosis.
35                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The adult stem cell (ASC) signature explores the relationship between human stem cell and cancer transcriptional programs. Higher the scores, aggressive the cancer, poorer the clinical outcome. The ASC signature is associated with the presence of specific genomic and alterations and methylation profiles.
36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Cytotoxic immune signature score represents the expression of a set of genes considered molecular markers of cytotoxic CD8+ T cells and NK cells. Higher score higher immune response. The score is associated with arm and chromosome aneuploidy thus low level of SCNA (somatic copy number alterations).
37                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Chemokine score to predict host immune reaction and the formation of unique ectopic lymph node-like structures associated with better overall survival. Higher the score the more lymph node-like structures are present better the prognosis in melanoma patients.
38                                                                                                                                                                                                                                                                                                                                                                                                          Four intestinal cell signatures characterizing the cells in the crypts of colorectal cancer. They may estimate the relative number of ISC-like cells within a given tumor as well as the over-expression of particular ISC genes co-opted by colorectal cancer cells. Higher the EphB2- and Lgr5 scores higher the risk of relapses. While, the signature proliferation is inversely associated with the risk of relapses and the Late TA shows no association.
39                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      The score is based on the average of ssGSEA scores, weighted by size, of gene sets involved in response to anti-PD1 blockade therapy derived from on-treatment tumor specimens. It predicts the response to anti-PD1 blockade in metastatic melanoma: the score is high in responders with better overall survival.
40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Enrichment of the innate anti-PD-1 resistance (IPRES) signature, indicates heightened mesenchymal transition, angiogenesis, hypoxia, and wound healing. GSVA es of 26 gene-sets involved in response to anti-PD1.
41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Two ECM ssGSEA scores are derived from cancer-associated extracellular matrix (ECM) genes and predict response to immune checkpoint blockade. Higher the ECM_up score and lower the ECM_down score worst the prognosis. Scores are inversely correlated with tumor purity and ECM_up directly correlated with CAFs presence and TGF-b activation.
42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                CIS signature reveals the presence or absence of carcinoma in situ (CIS) lesions, which are, in the urinary bladder, associated with a high risk of disease progression to a muscle invasive stage. Higher scores suggest the development of CIS lesions.
43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   A score based on homologous recombination deficiency (HRD), higher the score better the platinum response, the patient outcome, and higher presence of BRCA mutations or inactivation.
44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            VEGF profile is a prognostic score that correlates with glycolytic enzymes, hypoxia and vessel formation in distant metastasis, higher the score worst the overall and relapse-free survival.
45                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           A DNA Repair based score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. The higher the score the better the prognosis.
46                                                                                                                                                                                                                                                                                                                                                                                                                                                 Single sample gene set enrichment (ssGSEA) analysis was used for the immune genes from ImmPort database to develop an immune-based prognostic score for OV (IPSOV). IPSOV is a prognostic signature which stratifyies patients into low- and high-immune risk score and could be used to predict overall survival outcome in patients with ovarian cancer. The patients with low IPSOV scores have longer survival time.
47 Six glioblastoma cellular states scores are returned. MES2-like state is associated with high expression of mesenchymal-related, hypoxia-response, stress and glycolytic genes. This is an evidence that in some tumors the mesenchymal state is linked to hypoxia conditions and increased glycolisis. MES1-like state is also associated with high expression of mesenchymal-related genes, but it is hypoxia independent. The AC-like state includes astrocytic markers. The OPC-like state includes oligodendroglial markers. The NPC1-like state contains neural progenitor markers; OPC-related genes are included and they reflect the potential of NPCs to differentiate towards OPCs. The NPC2-like state also contains neural progenitor markers; neuronal lineage genes are included and they reflect the potential of NPCs to differentiate towards neurons.
> 
> 
> 
> 
> cleanEx()
> nameEx("cellCycleSign")
> ### * cellCycleSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: cellCycleSign
> ### Title: Cell-cycle Signature classifier
> ### Aliases: cellCycleSign
> 
> ### ** Examples
> 
> data(ovse)
> cellCycleSign(dataset = ovse, inputType = "rnaseq")
cellCycleSignLundberg is using 93% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("chemokineSign")
> ### * chemokineSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: chemokineSign
> ### Title: Chemokine Signature
> ### Aliases: chemokineSign
> 
> ### ** Examples
> 
> data(ovse)
> chemokineSign(dataset = ovse, inputType = "rnaseq")
ChemokineSign is using 100% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("consensusOVSign")
> ### * consensusOVSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: consensusOVSign
> ### Title: ConsensusOV Signature
> ### Aliases: consensusOVSign
> 
> ### ** Examples
> 
> data(ovse)
> consensusOVSign(dataset = ovse)
'select()' returned 1:1 mapping between keys and columns
Loading training data
Training Random Forest...
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("correlationSignPlot")
> ### * correlationSignPlot
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: correlationSignPlot
> ### Title: Correlation Plot
> ### Aliases: correlationSignPlot
> 
> ### ** Examples
> 
> data(ovse)
> correlationSignPlot(data = ovse)

‚îÄ‚îÄ openair object ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
Created by:
‚ñ∂ `corPlot(mydata = as.data.frame(SignMatrix), cluster = TRUE, dendrogram =
TRUE, ` and ` lower = TRUE, fontsize = 6)`

‚îÄ‚îÄ This contains: ‚îÄ‚îÄ

A single data frame:
‚Ä¢ $data [with no subset structure]

A single plot:
‚Ä¢ $plot [with no subset structure]

Other object(s):
‚Ä¢ $clust

> 
> 
> 
> 
> cleanEx()
> nameEx("evaluationSignPlot")
> ### * evaluationSignPlot
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: evaluationSignPlot
> ### Title: Evaluation Plot
> ### Aliases: evaluationSignPlot
> 
> ### ** Examples
> 
> data(ovse)
> evaluationSignPlot(data = ovse)
> 
> 
> 
> 
> cleanEx()
> nameEx("expandedImmuneSign")
> ### * expandedImmuneSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: expandedImmuneSign
> ### Title: ExpandedImmune Signature
> ### Aliases: expandedImmuneSign
> 
> ### ** Examples
> 
> data(ovse)
> expandedImmuneSign(dataset = ovse)
expandedImmuneSign is using 100% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("ferroptosisSign")
> ### * ferroptosisSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: ferroptosisSign
> ### Title: Ferroptosis Signature
> ### Aliases: ferroptosisSign
> 
> ### ** Examples
> 
> data(ovse)
> ferroptosisSign(dataset = ovse)
ferroptosisSignYe is using 100% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("geneHeatmapSignPlot")
> ### * geneHeatmapSignPlot
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: geneHeatmapSignPlot
> ### Title: Genes' Signatures' Heatmap
> ### Aliases: geneHeatmapSignPlot
> 
> ### ** Examples
> 
> data(ovse)
> geneHeatmapSignPlot(data = ovse, whichSign = "Ferroptosis_Ye")
> 
> 
> 
> 
> cleanEx()
> nameEx("glioCellStateSign")
> ### * glioCellStateSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: glioCellStateSign
> ### Title: Glioblastoma Cellular States Signature
> ### Aliases: glioCellStateSign
> 
> ### ** Examples
> 
> data(ovse)
> 
> 
> 
> 
> cleanEx()
> nameEx("glycolysisSign")
> ### * glycolysisSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: glycolysisSign
> ### Title: Glycolysis Signature
> ### Aliases: glycolysisSign
> 
> ### ** Examples
> 
> data(ovse)
> glycolysisSign(dataset = ovse)
glycolysisSignZhang is using 44% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(41): OV_subtype os ... IPSOV_Shen Glycolysis_Zhang
> 
> 
> 
> 
> cleanEx()
> nameEx("heatmapSignPlot")
> ### * heatmapSignPlot
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: heatmapSignPlot
> ### Title: Global Heatmap of Signatures' scores.
> ### Aliases: heatmapSignPlot
> 
> ### ** Examples
> 
> data(ovse)
> heatmapSignPlot(data = ovse)
> 
> 
> 
> 
> cleanEx()
> nameEx("hypoxiaSign")
> ### * hypoxiaSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: hypoxiaSign
> ### Title: Hypoxia Signature
> ### Aliases: hypoxiaSign
> 
> ### ** Examples
> 
> data(ovse)
> hypoxiaSign(dataset = ovse, inputType = "rnaseq")
hypoxiaSign is using 92% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("immuneCytSign")
> ### * immuneCytSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: immuneCytSign
> ### Title: Immune Cytolytic Activity Signature
> ### Aliases: immuneCytSign
> 
> ### ** Examples
> 
> data(ovse)
> immuneCytSign(dataset = ovse, inputType = "rnaseq")
ImmuneCytSignRooney is using 100% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("immunoScoreSign")
> ### * immunoScoreSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: immunoScoreSign
> ### Title: Immunogenic Signature
> ### Aliases: immunoScoreSign
> 
> ### ** Examples
> 
> data(ovse)
> immunoScoreSign(dataset = ovse)
immunoScoreSignHao is using 100% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("lipidMetabolismSign")
> ### * lipidMetabolismSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: lipidMetabolismSign
> ### Title: Lipid Metabolism Signature
> ### Aliases: lipidMetabolismSign
> 
> ### ** Examples
> 
> data(ovse)
> lipidMetabolismSign(dataset = ovse)
lipidMetabolismSign is using 100% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("matrisomeSign")
> ### * matrisomeSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: matrisomeSign
> ### Title: Core Matrisome Gene signature
> ### Aliases: matrisomeSign
> 
> ### ** Examples
> 
> data(ovse)
> matrisomeSign(dataset = ovse)
matrisomeSign is using 100% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("mitoticIndexSign")
> ### * mitoticIndexSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: mitoticIndexSign
> ### Title: Mitotic Index
> ### Aliases: mitoticIndexSign
> 
> ### ** Examples
> 
> data(ovse)
> mitoticIndexSign(dataset = ovse)
mitoticIndexSign is using 100% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("multipleSign")
> ### * multipleSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: multipleSign
> ### Title: Multiple Signatures Computation
> ### Aliases: multipleSign
> 
> ### ** Examples
> 
> data(ovse)
> multipleSign(dataset = ovse)
EMTSignMiow is using 96% of epithelial signature genes
EMTSignMiow is using 91% of mesenchymal signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .filterFeatures(expr, method) :
  1 genes with constant expression values throughout the samples.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
EMTSignMak is using 96% of epithelial signature genes
EMTSignMak is using 100% of mesenchymal signature genes
EMTSignCheng is using 31% of signature genes
pyroptosisSignYe is using 86% of signature genes
pyroptosisSignShao is using 33% of signature genes
pyroptosisSignLin is using 60% of signature genes
pyroptosisSignLi is using 0% of signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, sdata$SYMBOL,  :
  pyroptosisSignLi is computed with less than 30% of its genes
pyroptosisSignLi raised an error:
missing value where TRUE/FALSE needed
Therefore it was omitted
ferroptosisSignYe is using 100% of signature genes
ferroptosisSignLiang is using 30% of signature genes
ferroptosisSignLiu is using 0% of signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, sdata$SYMBOL,  :
  ferroptosisSignLiu is computed with less than 30% of its genes
ferroptosisSignLiu raised an error:
incorrect number of dimensions
Therefore it was omitted
ferroptosisSignLi is using 0% of signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, sdata$SYMBOL,  :
  ferroptosisSignLi is computed with less than 30% of its genes
ferroptosisSignLi raised an error:
missing value where TRUE/FALSE needed
Therefore it was omitted
lipidMetabolismSign is using 100% of signature genes
hypoxiaSign is using 92% of signature genes
immunoScoreSignHao is using 100% of signature genes
immunoScoreSignRoh is using 100% of signature genes
'select()' returned 1:1 mapping between keys and columns
Loading training data
Training Random Forest...
IPSSign is using 98% of signature genes
matrisomeSign is using 100% of signature genes
mitoticIndexSign is using 100% of signature genes
ImmuneCytSignRooney is using 100% of signature genes
IFNSign is using 100% of signature genes
expandedImmuneSign is using 100% of signature genes
TinflamSign is using 100% of signature genes
TLSSign is using 11% of signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, genes, author = author) :
  TLSSign is computed with less than 30% of its genes
StemCellCD49fSign is using 9% of signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, sdata$SYMBOL,  :
  StemCellCD49fSign is computed with less than 30% of its genes
glycolysisSignZhang is using 44% of signature genes
glycolysisSignXu is using 62% of signature genes
CINSign is using 96% of signature genes
CINSign is using 94% of signature genes
cellCycleSignLundberg is using 93% of signature genes
cellCycleSignDavoli is using 100% of signature genes
autophagySignXu is using 13% of signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, sdata$SYMBOL,  :
  autophagySignXu is computed with less than 30% of its genes
autophagySignChenM is using 18% of OS signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, sdata$SYMBOL,  :
  autophagySignChenMOS is computed with less than 30% of its genes
autophagySignChenM is using 0% of DFS signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, sdata$SYMBOL,  :
  autophagySignChenMDFS is computed with less than 30% of its genes
autophagySignChenM raised an error:
missing value where TRUE/FALSE needed
Therefore it was omitted
autophagySignWang is using 0% of signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, sdata$SYMBOL,  :
  autophagySignWang is computed with less than 30% of its genes
autophagySignWang raised an error:
missing value where TRUE/FALSE needed
Therefore it was omitted
autophagySignChenH is using 50% of signature genes
ASCSign is using 92% of signature genes
ImmuneCytSignDavoli is using 100% of signature genes
ChemokineSign is using 100% of signature genes
ISCSign is using 24% of ISCEphB2 signature genes
Warning in .percentageOfGenesUsed("ISCSign", datasetm_n, sign_list$ISCEphB2,  :
  ISCSignISCEphB2 is computed with less than 30% of its genes
ISCSign is using 8% of LateTA signature genes
Warning in .percentageOfGenesUsed("ISCSign", datasetm_n, sign_list$LateTA,  :
  ISCSignLateTA is computed with less than 30% of its genes
ISCSign is using 14% of ISCLgr5 signature genes
Warning in .percentageOfGenesUsed("ISCSign", datasetm_n, sign_list$ISCLgr5,  :
  ISCSignISCLgr5 is computed with less than 30% of its genes
ISCSign is using 42% of Prolif signature genes
PassONSign is using 100% of signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .filterFeatures(expr, method) :
  1 genes with constant expression values throughout the samples.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
[1] "Normalizing..."
IPRESSign is using 100% of signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .filterFeatures(expr, method) :
  92 genes with constant expression values throughout the samples.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
[1] "Normalizing..."
ECMSign is using 100% of up signature genes
ECMSign is using 93% of down signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .filterFeatures(expr, method) :
  1 genes with constant expression values throughout the samples.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
CISSign is using 28% of up signature genes
Warning in .percentageOfGenesUsed("CISSign", datasetm, sign_up$SYMBOL, "up") :
  CISSignup is computed with less than 30% of its genes
CISSign is using 22% of down signature genes
Warning in .percentageOfGenesUsed("CISSign", datasetm, sign_down$SYMBOL,  :
  CISSigndown is computed with less than 30% of its genes
HRDSSign is using 89% of signature genes
VEGFSign is using 100% of signature genes
DNArepSign is using 87% of signature genes
IPSOVSign is using 100% of signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .gsva(expr, mapped.gset.idx.list, method, kcdf, rnaseq, abs.ranking,  :
  Some gene sets have size one. Consider setting 'min.sz > 1'.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(57): OV_subtype os ... IPRES_Hugo CIS_Robertson
> multipleSign(dataset = ovse, tissue = "ovary")
EMTSignMiow is using 96% of epithelial signature genes
EMTSignMiow is using 91% of mesenchymal signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .filterFeatures(expr, method) :
  1 genes with constant expression values throughout the samples.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
pyroptosisSignYe is using 86% of signature genes
ferroptosisSignYe is using 100% of signature genes
lipidMetabolismSign is using 100% of signature genes
immunoScoreSignHao is using 100% of signature genes
'select()' returned 1:1 mapping between keys and columns
Loading training data
Training Random Forest...
matrisomeSign is using 100% of signature genes
HRDSSign is using 89% of signature genes
DNArepSign is using 87% of signature genes
IPSOVSign is using 100% of signature genes
Warning: Calling gsva(expr=., gset.idx.list=., method=., ...) is deprecated; use a method-specific parameter object (see '?gsva').
Warning in .gsva(expr, mapped.gset.idx.list, method, kcdf, rnaseq, abs.ranking,  :
  Some gene sets have size one. Consider setting 'min.sz > 1'.
[1] "Calculating ranks..."
[1] "Calculating absolute values from ranks..."
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("oneSignPlot")
> ### * oneSignPlot
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: oneSignPlot
> ### Title: Scatterplot for a single signature
> ### Aliases: oneSignPlot
> 
> ### ** Examples
> 
> data(ovse)
> oneSignPlot(data = ovse, whichSign = "Ferroptosis_Ye")
`stat_bin()` using `bins = 30`. Pick better value with `binwidth`.
> 
> 
> 
> 
> cleanEx()
> nameEx("pyroptosisSign")
> ### * pyroptosisSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: pyroptosisSign
> ### Title: Pyroptosis Signature
> ### Aliases: pyroptosisSign
> 
> ### ** Examples
> 
> data(ovse)
> pyroptosisSign(dataset = ovse)
pyroptosisSignYe is using 86% of signature genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(40): OV_subtype os ... DNArep_Kang IPSOV_Shen
> 
> 
> 
> 
> cleanEx()
> nameEx("ridgelineSignPlot")
> ### * ridgelineSignPlot
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: ridgelineSignPlot
> ### Title: Ridgeline Plot
> ### Aliases: ridgelineSignPlot
> 
> ### ** Examples
> 
> data(ovse)
> ridgelineSignPlot(data = ovse)
> 
> 
> 
> 
> cleanEx()
> nameEx("stemCellCD49fSign")
> ### * stemCellCD49fSign
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: stemCellCD49fSign
> ### Title: CD49fHi Basal Stem Cell Signature
> ### Aliases: stemCellCD49fSign
> 
> ### ** Examples
> 
> data(ovse)
> stemCellCD49fSign(dataset = ovse)
StemCellCD49fSign is using 9% of signature genes
Warning in .percentageOfGenesUsed(namesignature, datasetm, sdata$SYMBOL,  :
  StemCellCD49fSign is computed with less than 30% of its genes
class: SummarizedExperiment 
dim: 1456 40 
metadata(0):
assays(4): norm_expr TPM CPM FPKM
rownames(1456): ACOT7 ADORA3 ... TMSB4Y USP9Y
rowData names(0):
colnames(40): sample1 sample2 ... sample39 sample40
colData names(41): OV_subtype os ... IPSOV_Shen StemCellCD49f_Smith
> 
> 
> 
> 
> cleanEx()
> nameEx("survivalSignPlot")
> ### * survivalSignPlot
> 
> flush(stderr()); flush(stdout())
> 
> ### Name: survivalSignPlot
> ### Title: Survival Plot
> ### Aliases: survivalSignPlot
> 
> ### ** Examples
> 
> data(ovse)
> mysurvData <- cbind(ovse$os, ovse$status)
> rownames(mysurvData) <- rownames(SummarizedExperiment::colData(ovse))
> survivalSignPlot(
+     data = ovse,
+     survData = mysurvData,
+     whichSign = "Ferroptosis_Ye"
+ )
> 
> 
> 
> 
> ### * <FOOTER>
> ###
> cleanEx()
> options(digits = 7L)
> base::cat("Time elapsed: ", proc.time() - base::get("ptime", pos = 'CheckExEnv'),"\n")
Time elapsed:  142.399 2.221 146.354 0 0 
> grDevices::dev.off()
null device 
          1 
> ###
> ### Local variables: ***
> ### mode: outline-minor ***
> ### outline-regexp: "\\(> \\)?### [*]+" ***
> ### End: ***
> quit('no')
